

Butylscopolamine (Hyoscine)

(Buscopan (d), Spasium (d), Spasmipur, Sympagesic (d)) POM-V, POM

Formulations

Injectable: 4 mg/ml butylscopolamine + 500 mg/ml metamizole in 100 ml multidose bottle; 20 mg/ml butylscopolamine only. Oral: 10 mg, 20 mg tablets.

Action

Inhibits M1 muscarinic acetylcholine receptors in the GI and urinary tracts causing smooth muscle relaxation but does not cross the blood–brain barrier.

Use

- Part of supportive therapy for diarrhoea in dogs, particularly when pain or abdominal discomfort is present.
- Control of pain associated with urinary obstruction in dogs.

Should only be used in combination with investigations into the cause of abdominal pain or definitive relief of urinary obstruction.

DOSES

- **Dogs: Control of diarrhoea and/or abdominal discomfort:** 0.1 ml/kg i.v., i.m. q12h (Buscopan Compositum, Sympagesic); 0.5 mg/kg i.m., p.o. q12h (butylscopolamine only).
- **Cats** Do not use.

Warnings

Adverse reactions

Dry mouth, blurred vision, hesitant micturition and constipation at doses acting as gut neuromuscular relaxants. The i.m. route may cause a local reaction.

Contraindications

Intestinal obstruction.

Drug interactions

Metamizole should not be given to dogs that have been treated with a phenothiazine, as hypothermia may result. Effects may be potentiated by concurrent use of other anticholinergic or analgesic drugs.

Safety and handling

Avoid self-injection: metamizole can cause reversible but potentially serious agranulocytosis and skin allergies. Protect solution from light.